• Thurs news: Moderna posts surprise profit. How Trump victory will affect FTC, FDA. Gilead CAR-T sales stagnate. Sarepta pulls plug on Duchenne candidate. AZ China chief in custody. See more on our front page

Zone Director

Have no reps left on their own? Better opportunity (not due to poor treatment), retirement on their own, switched carrers?

Sure, a few have. Three just left last month, all for better positions. But if they were valued, challenged and compensated, would they still have entertained leaving?

Either way, attrition rate is well known to be @33% per year. Whatever the reason, THAT is unacceptable and most definitely impacts MAH's success.
 












Merck doesn't advertise (read "tell many people") when colleagues leave. Or are forced out.

There have been several "Dana style screwings".

I don't understand how management allows that incompetent RM in the North East to discriminate as he does against his direct reports. If you are over 50 or of child bearing age you are in his target. He creates tension that threatens the reps that he wants out and then pushes them to leave or be terminated. He will some day cost Merck millions.
 




I don't understand how management allows that incompetent RM in the North East to discriminate as he does against his direct reports. If you are over 50 or of child bearing age you are in his target. He creates tension that threatens the reps that he wants out and then pushes them to leave or be terminated. He will some day cost Merck millions.

He probably already has. But no one knows. Omertà.
 
































To be fair he only went to AstraZenaca after being terminated from Merck human.

Let me get this straight. This gem worked for Merck on the human side and was for what ever reason let go. He then hooked on with AstraZeneca on the human side. From there some brilliant bird brain in Merck animal health decided that a sales rep with no previous animal health experience and not working in management for AstraZeneca would be perfect for a management position in animal health sales. It explains why his region is crumbling. How can he give direction to employees that all no more then he?
 




Maybe his region is crumbling like others because there are virtually no farms left there anymore and Mother Merck (and his predecessors) did shit to market anything useful to small animal vets there while the farms were drying up and blowing away.

Ask a vet who merck is. Most will say, who ?
 




Maybe his region is crumbling like others because there are virtually no farms left there anymore and Mother Merck (and his predecessors) did shit to market anything useful to small animal vets there while the farms were drying up and blowing away.

Ask a vet who merck is. Most will say, who ?
The days of reps calling on large and companion animal vets is long gone. The decline of dairy farms is irrelevant. His region only calls on companion animal practices. Enjoy retirement.
 




Let me get this straight. This gem worked for Merck on the human side and was for what ever reason let go. He then hooked on with AstraZeneca on the human side. From there some brilliant bird brain in Merck animal health decided that a sales rep with no previous animal health experience and not working in management for AstraZeneca would be perfect for a management position in animal health sales. It explains why his region is crumbling. How can he give direction to employees that all no more then he?

This type of managerial competence may indicate that MAH upper management are not Menza members.
 












The days of reps calling on large and companion animal vets is long gone. The decline of dairy farms is irrelevant. His region only calls on companion animal practices. Enjoy retirement.

The point is that Merck had little/did little/could've done much more to develop/promote CA products for years. Suddenly jumping into the fray with Activyl, Bravecto & Scalibor is not going to generate any world records overnight. It takes time, a long time, to build market share. Especially with new products some vets still have little interest in yet. Fresh from human side managers need to get a grip on these facts, that Merck has a lot of catching up to do.
 




The point is that Merck had little/did little/could've done much more to develop/promote CA products for years. Suddenly jumping into the fray with Activyl, Bravecto & Scalibor is not going to generate any world records overnight. It takes time, a long time, to build market share. Especially with new products some vets still have little interest in yet. Fresh from human side managers need to get a grip on these facts, that Merck has a lot of catching up to do.

The human side managers need to understand the vet market and stop creating spread sheets and demanding e mail mass mailings . learn the market so you know where your product fits or we can go all human all the time. We can walk into each clinic and ask what samples they want, have them sign our I pad and move to the next office. Just like the human side. We will be wait staff for lunches and order mules for samples.